IL35 Level in Vitiligo
Not yet recruiting
- Conditions
- IL35, Vitiligo
- Registration Number
- NCT05980390
- Lead Sponsor
- Cairo University
- Brief Summary
The aim of this observational study is to evaluate the level of the IL-35 protein in tissue biopsy from patients with active \& stable vitiligo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
- Patients with active and stable vitiligo
Exclusion Criteria
- Pregnant and lactating women.
- Patients with associated autoimmune or other dermatological diseases e.g., Alopecia areata and lupus erythematous.
- Patients already on both topical and systemic treatment at the time of recruitment.
- Patients on Immunosuppressive drugs.
- Other hypopigmented diseases such as pityriasis alba, tinea versicolor, lichen sclerosis, post inflammatory hypopigmentation and leprosy as excluded by lack of accentuation by wood's light examination.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method level of IL35 in tissue biopsy 3 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What role does IL-35 play in the pathogenesis of active versus stable vitiligo according to recent studies?
Are there any known molecular mechanisms linking IL-35 levels to melanocyte survival in vitiligo patients?
How do IL-35 tissue levels in vitiligo compare to other autoimmune skin conditions like psoriasis or lupus?
What are the potential therapeutic implications of IL-35 modulation in vitiligo treatment strategies?
Can IL-35 serve as a predictive biomarker for treatment response in vitiligo subtypes such as segmental or non-segmental forms?